News | Halozyme
WEBHalozyme provides disruptive drug delivery solutions with the goal of improving patient experiences and outcomes that can enhance the competitiveness of emerging and established therapies. To catch up on our latest news, updates and Industry Insights, please review the links below: Press Releases.
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze …
WEB6 days ago · ROG.SW. HALO. Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) with biopharmaceutical company Halozyme Therapeutics ...
Halozyme Announces Positive Clinical Data of its High-Volume …
WEBOct 16, 2023 · Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced positive results of a clinical study demonstrating subcutaneous administration of 10 mL of a representative biologic...
Halozyme Announces Positive Clinical Data of its High-Volume …
WEBOct 16, 2023 · Data Highlights. 96% of participants stated that they would be willing to receive the injection again. 90% of participants indicated feeling either no pain or mild …
Halozyme's (HALO) ENHANZE Product Gets New Patent Grant in EU
WEBJun 6, 2024 · Halozyme Therapeutics HALO announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which is produced using the company's proprietary ENHANZE...
Halozyme to Acquire Antares Pharma to Create a Specialty …
WEBApr 13, 2022 · Halozyme expects to build on Antares' core platform technology and capabilities to drive incremental, durable revenue opportunities with additional intellectual property protections for Antares...
HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND …
WEBMay 9, 2023 · HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS. Halozyme Therapeutics, Inc. May 09, 2023, 16:01 ET. Revenue Increased 38% YOY to $162.1 million; GAAP Diluted Earnings per...
FDA approves Roche’s Ocrevus Zunovo with Halozyme’s Enhanze …
WEB2 days ago · Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis.
Halozyme Therapeutics Agrees to Buy Antares Pharma
WEBApr 13, 2022 · HALO 2.91% Halozyme Therapeutics Inc. HALO 2.91% agreed to a nearly $1 billion deal to buy specialty pharmaceutical company Antares Pharma Inc. in a move that will deepen its focus on drug...
Reinventing the patient experience. | Halozyme
WEBThe patient is at the forefront of everything we do at Halozyme. With our disruptive drug delivery technologies and robust commercial portfolio, we are committed to reinventing the patient experience by easing the burden of treatment and improving patient outcomes.